Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise
Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise
This protein is typically hidden in healthy tissues but becomes accessible and overexpressed in many cancers, making it an ideal therapeutic focus.William Blair initiated coverage on Elevation Oncology, Inc. (NASDAQ:ELEV), a cancer drug focus firm leveraging antibody-drug conjugate expertise initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3.
威廉·布萊爾開始對Elevation Oncology, Inc.（納斯達克：ELEV）進行覆蓋，這是一個專注於癌症藥物的公司，利用抗體藥物結合體的專業知識，最初針對兩個在腫瘤學中已經驗證的靶點，Claudin 18.2和HER3。
Analyst Andy Hsieh writes that investing in Elevation Oncology offers a favorable risk-to-reward ratio, especially at its current valuation. He has initiated coverage with an Outperform rating.
分析師Andy Hsieh表示，投資Elevation Oncology提供了有利的風險回報比，尤其是在目前的估值下。他已對其發起覆蓋，並給予優於大盤的評級。
The company provides exposure to the fast-growing market of antibody-drug conjugates and focuses on a scientifically and regulatory-validated target. The ADC field has gained significant interest, with claudin 18.2 emerging as a promising target.
該公司爲抗體藥物結合體的快速增長市場提供了投資機會，並專注於一個科學和監管上已被驗證的靶點。抗體藥物結合體領域引起了顯著關注，Claudin 18.2作爲一個前景廣闊的靶點正在嶄露頭角。
This protein is typically hidden in healthy tissues but becomes accessible and overexpressed in many cancers, making it an ideal therapeutic focus.
這種蛋白質通常隱藏在健康組織中，但在許多癌症中變得可接近並過度表達，使其成爲理想的治療靶點。
Elevation's lead program, EO-3021, aligns with these trends and has shown promising results in early Phase I trials. Additionally, the recent approval of Astellas Pharma Inc's (OTC:ALPMF) (OTC:ALPMY) Vyloy, a CLDN18.2-targeted antibody, reduces clinical and regulatory risks for Elevation's program, offering high potential rewards for a modest initial investment.
Elevation的主要項目EO-3021與這些趨勢相吻合，並在早期一期試驗中顯示出有希望的結果。此外，安斯泰萊製藥（ADR）最近批准了Vyloy，這是一種針對CLDN18.2的抗體，降低了Elevation項目的臨牀和監管風險，爲適度的初始投資提供高潛在回報。
In August, Elevation Oncology reported initial data from the dose escalation portion of the ongoing Phase 1 trial of EO-3021.
在8月份，Elevation Oncology報告了正在進行的EO-3021一期試驗的劑量遞增部分的初步數據。
As of the data cutoff date of June 10, 32 patients had been treated. EO-3021 was observed to be generally well-tolerated. No Grade 4 or 5 treatment-related adverse events were reported, and less than 10% of patients discontinued EO-3021 due to adverse events.
截至截止日期2023年6月10日，已有32名患者接受了治療。EO-3021被觀察爲一般耐受良好。沒有報告4級或5級治療相關的不良事件，且不到10%的患者因不良事件中止使用EO-3021。
Hsieh estimates the total addressable market for frontline CLDN18.2-positive gastric and GEJ cancer in five major regions at about $6.6 billion, with $1.8 billion in the U.S. alone.
Hsieh估計，五個主要地區的前線CLDN18.2陽性胃癌和GEJ癌症的可尋址市場總額約爲66億元，其中美國獨佔18億元。
For second-line pancreatic cancer, which has limited treatment options, the TAM is projected at $1.8 billion across the U.S. and Europe, including $1.3 billion in the U.S. The analysts believe even a small market share in these areas could significantly boost the company's current valuation.
對於第二線胰腺癌，治療選擇有限，預計在美國和歐洲的市場規模爲18億美元，其中美國爲13億美元。分析師認爲，即使在這些領域佔據小份額也能顯著提升公司的當前估值。
Recently, Elevation Oncology nominated EO-1022 as its HER3 ADC development candidate. EO-1022 is progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug application in 2026.
最近，Elevation Oncology提名EO-1022作爲其HER3 ADC開發候選藥物。EO-1022正在進行臨牀前開發，Elevation Oncology預計將在2026年提交一項研究新藥申請。
Price Action: ELEV stock is up 7.54% at $0.64 at last check Friday.
價格走勢：截至上週五，ELEV股票上漲7.54%，報0.64美元。
- Biden Blocks $14.9B US Steel Takeover, Shares Plunge (UPDATED)
- 拜登阻止了149億美元的美國鋼鐵收購，股價暴跌（更新）
Photo: Shutterstock
Photo: Shutterstock
譯文內容由第三人軟體翻譯。